Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OXIGENE INC. (OXGN) -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (205)	5/22/2001 8:37:55 PM
From: Miljenko Zuanic	Respond to of 273

<<The comparison certainly leads one to conclude that the market has made a big mistake, to date, in valuing combretastatin. >> Thanks God for market mistake. This one and many more (in pass and to come). Miljenko [eom]

To: keokalani'nui who wrote (205)	6/2/2001 12:54:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 273

>> The comparison certainly leads one to conclude that the market has made a big mistake, to date, in valuing combretastatin. << I'm finished with the mild nausea that swept over me after seeing the GLIA comparison, and can now state "not really!" Let's not forget OXGN's heritage, Sensamide and Neu-Sensamide. If ever there was a bait and switch company, some might consider that Oxigene was it. Profit from keeping head up, and comparing apples with apples?